Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease therapies, has granted inducement equity awards to two new employees. The compensation package includes 14,800 stock options at an exercise price of $3.06 per share and 7,400 RSUs.
The stock options will vest over four years with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years with one-third vesting annually. These grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.
["New talent acquisition with equity-based compensation alignment", "Structured vesting schedule promotes employee retention"]Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica specializzata in terapie per il cancro e malattie rare, ha assegnato premi azionari di incentivo a due nuovi dipendenti. Il pacchetto retributivo comprende 14.800 opzioni su azioni con un prezzo di esercizio di 3,06 $ per azione e 7.400 RSU.
Le opzioni su azioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto mensilmente nei successivi 36 mesi. Le RSU matureranno in tre anni, con un terzo che matura ogni anno. Questi premi sono stati approvati secondo la Regola 5635(c)(4) del Nasdaq come incentivi materiali per l'assunzione.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa cl铆nica centrada en terapias para el c谩ncer y enfermedades raras, ha otorgado premios de acciones como incentivo a dos nuevos empleados. El paquete de compensaci贸n incluye 14,800 opciones sobre acciones a un precio de ejercicio de $3.06 por acci贸n y 7,400 RSU.
Las opciones sobre acciones se consolidar谩n durante cuatro a帽os, con el 25% consolidado despu茅s de un a帽o y el resto mensualmente durante los siguientes 36 meses. Las RSU se consolidar谩n en tres a帽os, con un tercio consolidado anualmente. Estas concesiones fueron aprobadas bajo la Regla 5635(c)(4) de Nasdaq como incentivos materiales para la contrataci贸n.
Protara Therapeutics (Nasdaq: TARA)電� 鞎� 氚� 頋穩 歆堩櫂 旃橂鞝滌棎 欷戩爯鞚� 霊� 鞛勳儊 雼硠 須岇偓搿�, 霊� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞙犾澑 欤检嫕 氤挫儊鞚� 攵�鞐枅鞀惦媹雼�. 氤挫儊 韺偆歆�鞐愲姅 欤茧嫻 頄夓偓 臧�瓴╈澊 $3.06鞚� 14,800欤� 鞀ろ啞 鞓奠厴瓿� 7,400 RSU臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
鞀ろ啞 鞓奠厴鞚� 4雲勳棎 瓯胳硱 氩犾姢韺呺悩氅�, 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆�電� 36臧滌洈 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. RSU電� 3雲勳棎 瓯胳硱 氩犾姢韺呺悩氅� 毵る厔 3攵勳潣 1鞌� 氩犾姢韺呺惄雼堧嫟. 鞚� 氤挫儊鞚� 瓿犾毄 鞙犾澑鞚� 鞙勴暅 欷戩殧頃� 氤挫儊鞙茧 Nasdaq 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞀轨澑霅橃棃鞀惦媹雼�.
Protara Therapeutics (Nasdaq : TARA), une entreprise en phase clinique sp茅cialis茅e dans les th茅rapies contre le cancer et les maladies rares, a accord茅 des actions d'incitation 脿 deux nouveaux employ茅s. Le package de r茅mun茅ration comprend 14 800 options d'achat d'actions 脿 un prix d'exercice de 3,06 $ par action et 7 400 RSU.
Les options d'achat d'actions seront acquises sur une p茅riode de quatre ans, avec 25 % acquis apr猫s un an et le reste mensuellement sur 36 mois. Les RSU seront acquises sur trois ans, avec un tiers acquis chaque ann茅e. Ces attributions ont 茅t茅 approuv茅es conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq en tant qu'incitations mat茅rielles 脿 l'embauche.
Protara Therapeutics (Nasdaq: TARA), ein Unternehmen in der klinischen Phase mit Fokus auf Krebs- und seltene Krankheiten, hat zwei neuen Mitarbeitern Anreizaktien gew盲hrt. Das Verg眉tungspaket umfasst 14.800 Aktienoptionen zu einem Aus眉bungspreis von 3,06 $ pro Aktie sowie 7.400 RSUs.
Die Aktienoptionen werden 眉ber vier Jahre vesten, wobei 25 % nach einem Jahr vesten und der Rest monatlich 眉ber 36 Monate. Die RSUs vesten 眉ber drei Jahre, wobei jeweils ein Drittel j盲hrlich vestet. Diese Zuteilungen wurden gem盲脽 Nasdaq-Listenregel 5635(c)(4) als wesentliche Anreize f眉r die Einstellung genehmigt.
- None.
- Potential future dilution from equity awards
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (鈥淧rotara鈥� or the 鈥淐ompany鈥�), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees.
The Compensation Committee of Protara鈥檚 Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees鈥� employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of
All option awards vest over four years, with
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara鈥檚 portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or na茂ve to treatment with Bacillus Calmette-Gu茅rin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit聽.
Company Contact:
Justine O'Malley
Protara Therapeutics
646-817-2836
Source: Protara Therapeutics
FAQ
What equity awards did Protara Therapeutics (TARA) grant to new employees in August 2025?
What is the vesting schedule for Protara's (TARA) new employee stock options?
How do the RSUs vest in Protara's (TARA) new employee compensation package?
What was the exercise price for Protara's (TARA) inducement stock options granted in August 2025?
